Skip to main content
Premium Trial:

Request an Annual Quote

Evogene’s Q2 Revenues Rise, Loss Trimmed

Agricultural biotech firm Evogene announced this week that its second quarter revenues rose to $129,000 from $10,500 in the second quarter last year.
 
The Israeli firm posted a net loss of $738,000, or $.05 per share, for the three months ended June 30, compared with a net loss of $836,000, or $.06 per share, for the comparable period a year ago.
 
The firm, which spun out of Compugen in 2002, recently inked collaborations with Bayer CropScience, alternative energy firm Ormat, and banana producer Rahan Meristem.
 
Evogene said it had $9.9 million in cash, cash equivalents, cash deposits, and short-term marketable securities as of the end of the quarter. Its cash holdings reflect funds from its initial public offering, which was completed on the Tel Aviv Stock Exchange in June.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.